Neonc Technologies
NEONC Technologies: An early-stage biotech firm innovating in cancer treatment through unique delivery of plant-derived agents.
Founded
2008NEONC Technologies: An early-stage biotech firm innovating in cancer treatment through unique delivery of plant-derived agents.
Neonc Technologies, founded as an early-stage cancer biotechnology company, is dedicated to revolutionizing cancer treatment through innovative delivery methods. The company's core mission is to enhance the efficacy of cancer therapeutics by utilizing a novel, highly purified form of monoterpenes, derived from fruits and plants, for intranasal inhalation and other nontraditional delivery routes. Initially targeting malignant brain cancers such as gliomas, Neonc aims to improve first-line treatments and expand its applications to other aggressive brain cancers.
Notable affiliations include a partnership with Anova Enterprises to explore pediatric indications for their flagship product, NEO100, specifically targeting Pediatric High-Grade Gliomas (pHGGs). The company has achieved significant milestones with its proprietary, patented platform technology that facilitates the direct transport of therapeutics to the brain, bypassing the Blood-Brain Barrier. Neonc Technologies' innovative approach has the potential to significantly impact cancer treatment protocols and improve patient outcomes in challenging oncological conditions.
Companies similar to Neonc Technologies include Neoantigenics, Nerx Biosciences, Onchilles Pharma and Falcon Therapeutics.
Neonc Technologies was founded in 2008.
Neonc Technologies' headquarters is located in Los Angeles, CA, US.
As of Mar 1, 2025, Neonc Technologies has disclosed funding of $10.2M (USD). Undisclosed round amounts are excluded.
Neonc Technologies has 6 employees as of Feb 5, 2024.
